From: The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement
total sample (N = 2026) | CS group (N = 131) | WW group (N=1895) | p-value | |
---|---|---|---|---|
(mean ± SD) | (mean ± SD) | (mean ± SD) | ||
Age | 54.37 ± 14.67 | 63.44 ± 11.42 | 53.74 ± 14.66 | <0.0001a |
BMI | 29.52 ± 5.87 | 29.82 ± 5.37 | 29.49 ± 5.90 | 0.5407a |
ComS b | 1.06 ± 1.15 | 1.63 ± 1.25 | 1.02 ± 1.13 | 0.0004c |
PRS d | 1.01 ± 1.55 | 3.75 ± 1.43 | 0.82 ± 1.37 | <0.0001c |
VC [%predicted] | 100.52 ± 16.30 | 86.93 ± 17.25 | 101.48 ± 15.80 | <0.0001c |
FEV1/VC [%] | 79.61 ± 6.80 | 79.96 ± 7.75 | 79.58 ± 6.73 | 0.2795c |
TLC [%predicted] | 105.37 ± 15.70 | 90.78 ± 16.36 | 106.40 ± 15.14 | <0.0001c |
RV [%predicted] | 126.04 ± 30.42 | 108.24 ± 28.88 | 127.29 ± 30.14 | <0.0001c |
DLCOc [%predicted] | 79.62 ± 16.53 | 57.69 ± 15.94 | 81.13 ± 15.46 | <0.0001c |
KCOc [%predicted] | 89.00 ± 14.78 | 79.31 ± 16.00 | 89.67 ± 14.46 | <0.0001c |
n (%) | n (%) | n (%) | p -value e | |
Male sex | 919 (45.36%) | 85 (64.89%) | 834 (44.01%) | <0.0001 |
Acute COVID-19 severity f | ||||
mild | 1046 (51.63%) | 7 (5.34%) | 1039 (54.83%) | <0.0001 |
moderate | 433 (21.37%) | 27 (20.61%) | 406 (21.42%) | 0.9812 |
severe | 513 (25.32%) | 93 (70.99%) | 420 (22.16%) | <0.0001 |
Persistent respiratory symptoms | ||||
dyspnea | 1056 (52.12%) | 105 (80.15%) | 951 (50.18%) | <0.0001 |
cough | 616 (30.40%) | 48 (36.64%) | 568 (29.97%) | 0.1384 |